02 November 2012
Skcin are delighted to learn about the positive guidance for advanced melanoma drugs Yervoy and Zelboraf, which have demonstrated significant survival benefits in some patients and represent the biggest breakthrough in treatment for advanced melanoma in 30 years. With previous draft guidance issued by NICE being negative, we feel this decision represents a significant turnaround and will pave the way for patients in England and Wales to receive treatment within the NHS.
Malignant melanoma disproportionately affects young people and is now the second most common cancer in people aged 15-34 in the UK. Rates of malignant melanoma in Britain have risen faster than any other common cancer, with an estimated 2,000 people dying from the disease annually in this country. It is estimated that overall cases of melanoma will rise by 52% by 2030 - the biggest projected increase of any other cancer.